Continued access to alpelisib for eligible patients
Treatments studied
Part of Cancer, Skin clinical trials.
This study lets people who are already taking alpelisib in another Novartis trial keep getting it after that trial ends. It checks long-term safety and continued benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in a Novartis study and taking alpelisib.
- You are getting benefit from alpelisib, according to your study doctor.
- You have followed the visit schedule in your current study and are willing to keep doing so.
- You have not permanently stopped alpelisib in your current study.
- Any side effects from alpelisib are not severe or unresolved (or have improved enough to restart dosing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a drug called alpelisib for people with PROS (a rare condition that causes parts of the body to grow too much). The drug targets a specific gene change (PIK3CA mutation) that is often the cause. If you have this condition and it's causing serious symptoms, this study might help shrink or slow the overgrowth, improving your quality of life.
This program provides access to an experimental medicine called alpelisib (also known as BYL719) for people with serious conditions who have no other treatment options and cannot participate in clinical trials. If a licensed doctor requests it, and you meet the criteria, you may be able to receive this medicine through a managed access program.
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
This program lets people who are already doing well on a study treatment keep receiving it after the main study ends. It is only for those currently in the B2151009 study and benefiting from the treatment.
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
Hear when a new PIK3CA-Related Overgrowth Spectrum (PROS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.